Increase In Iron-binding Capacity Research Articles

Microwave-Induced Modification of Physical and Functional Characteristics and Antioxidant Potential of Alkali-Soluble Cell Wall Polysaccharides of Nelumbo nucifera Rhizome

The alkali-soluble cell wall polysaccharides (CWPs), extracted from Nelumbo nucifera rhizome flour (NNRF), were treated with microwave radiation to modify their physical characteristics, functional properties, and antioxidant potential. The NNRF was treated at different levels of microwave treatment time (1, 2, 3, 4 and 5 min) using the low-medium intensity (200 W). The cell wall was isolated and CWPs were extracted in 10% KOH solution followed by their physical, functional, and antioxidant characterization. Microwave treatment resulted in the morphological, structural and compositional modifications in CWPs that were directly correlated with their functional properties and antioxidant potential. A significant (p < 0.05) time-dependent exponential decrease in extract yield, exponential increase in water holding, oil holding, and swelling capacities, a polynomial increase in iron-binding capacity, and a linear increase in antioxidant properties including Trolox equivalent total antioxidant activity, ferrous reducing power, and free radical scavenging capacity of microwave-treated CWPs was observed. The increase in the studied functional and antioxidant potential of the treated samples may be due microwave-induced exposure of hydroxyl groups and uronic acid residues in CWPs. The data would be a valuable contribution to the literature regarding microwave-induced modification in physical, functional and antioxidant properties of CWPs of N. nucifera rhizome.

Helikobakter pylori İnfeksiyonunun Endoskopik, Patolojik ve Laboratuvar Bulguları Açısından Değerlendirilmesi

INTRODUCTION: Helicobacter pylori (H.pylori) has been shown to play a role in the development of chronic active gastritis, atrophic gastritis, gastrointestinal metaplasia, dysplasia, and gastric cancer, respectively. In our study, we aimed to evaluate the patients who underwent endoscopic examination in terms of endoscopic, pathological and laboratory (Hemogram and iron values) findings. METHODS: Between 2015 and 2016, 359 patients who were requested endoscopic examination and laboratory examination due to gastrointestinal system complaints were included in the study. RESULTS: In the intergroup evaluation [Group I (H.pylori (+)) - Group II (H.pylori (-))]; age was 43±13.6 years in Group I and 47.7±16.7 years in Group II (p=0.004). Iron binding capacity was found as 319.3±74.9 μg/dl in Group I and 293.7±82.4 μg/dl in Group II (p=0.002). When the presence of ulcer in the bulbus is evaluated; there were 49 cases in Group I and 32 cases in Group II (p=0.01). Neutrophil infiltration was found to be higher in Group I patients (p=0.000). In the correlation analysis of the presence of H.pylori; Neutrophil infiltration, presence of ulcer in the bulbus, iron binding capacity was positively, and age was negatively correlated. In the presence of chronic inflammation, although statistically significance was not detected (r=.102, p=0.054), it’s remarkable in terms of positive correlation. DISCUSSION AND CONCLUSION: Especially in young adults, together with pathological findings, an increase in iron binding capacity can be used as leading values for the development of anemia of unknown etiology. However, new studies are required to support this finding.

Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis

IntroductionOur objective was to determine the interrelationships of interleukin (IL)-6 receptor inhibition with haemoglobin, acute-phase reactants and iron metabolism markers (including hepcidin) in patients with rheumatoid arthritis (RA).MethodsData of patients receiving tocilizumab or placebo in the MEASURE study were analysed. We investigated associations at baseline and during tocilizumab treatment among haemoglobin, parameters of haemoglobin and iron homeostasis [ferritin, total iron-binding capacity (TIBC), hepcidin, haptoglobin], IL-6 and acute-phase reactants [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)] to identify statistical correlates of rise in haemoglobin level.ResultsAt baseline, CRP and haptoglobin were inversely correlated (modestly) with haemoglobin levels. After treatment with tocilizumab, CRP, hepcidin, ferritin and haptoglobin levels fell alongside increases in TIBC and haemoglobin. The falls in CRP, hepcidin and haptoglobin levels in the first 2 weeks correlated with a week 12 rise in TIBC and haemoglobin.ConclusionsInflammatory anaemia improves in patients with RA treated with tocilizumab. This improvement correlates with the degree of suppression of systemic inflammation, reduction in hepcidin and haptoglobin and increase in iron-binding capacity. These clinical data provide evidence of a role for IL-6 signalling in the inflammatory anaemia of RA.

Recombinant Human Granulocyte Colony-Stimulating Factor Increases Circulating Burst Forming Unit-Erythron and Red Blood Cell Production in Patients With Severe Human Immunodeficiency Virus Infection

Erythropoietin (EPO) is a major regulatory factor controlling red blood cell (RBC) production in humans. Although other humoral factors can alter the proliferation of committed early erythroid progenitors in vitro, no factor other than EPO has been clearly shown to induce proliferation of these cells in vivo. In a clinical trail of recombinant granulocyte colony-stimulating factor (G-CSF) and recombinant EPO in patients with advanced human immunodeficiency virus (HIV) infection, we noted reticulocytosis and increases in hemoglobin when G-CSF was administered before the administration of EPO. Subsequent studies demonstrated a significant increase in circulating burst forming unit-erythron (BFU-E) during daily recombinant G-CSF therapy. This increase was both time- and dose-dependent. The magnitude of increase in BFU-E correlated with the magnitude of increase in neutrophils and was associated with a mean increase in reticulocytes of 32,363/microL and a significant increase in mean hemoglobin of 1.04 +/- 0.34 g/dL over an 18-day interval. There was a significant increase in iron binding capacity and decreases in iron saturation and ferritin levels. In patients who were not recently transfused, there was an associated fall in endogenous erythropoietin levels. The increase in RBC production was most marked in patients who were severely anemic, transfusion-dependent, and who had elevated pretreatment EPO levels. There was no correlation between the increase in BFU-E and endogenous EPO levels or the time since last dose of zidovudine. The addition of recombinant EPO therapy three times weekly to patients did not result in further significant increases in BFU-E but did significantly increase hemoglobin. Our data suggest that recombinant G-CSF may be one of the hematopoietic factors that influences production of BFU-E and RBCs in humans.

Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection

Erythropoietin (EPO) is a major regulatory factor controlling red blood cell (RBC) production in humans. Although other humoral factors can alter the proliferation of committed early erythroid progenitors in vitro, no factor other than EPO has been clearly shown to induce proliferation of these cells in vivo. In a clinical trail of recombinant granulocyte colony-stimulating factor (G-CSF) and recombinant EPO in patients with advanced human immunodeficiency virus (HIV) infection, we noted reticulocytosis and increases in hemoglobin when G-CSF was administered before the administration of EPO. Subsequent studies demonstrated a significant increase in circulating burst forming unit-erythron (BFU-E) during daily recombinant G-CSF therapy. This increase was both time- and dose-dependent. The magnitude of increase in BFU-E correlated with the magnitude of increase in neutrophils and was associated with a mean increase in reticulocytes of 32,363/microL and a significant increase in mean hemoglobin of 1.04 +/- 0.34 g/dL over an 18-day interval. There was a significant increase in iron binding capacity and decreases in iron saturation and ferritin levels. In patients who were not recently transfused, there was an associated fall in endogenous erythropoietin levels. The increase in RBC production was most marked in patients who were severely anemic, transfusion-dependent, and who had elevated pretreatment EPO levels. There was no correlation between the increase in BFU-E and endogenous EPO levels or the time since last dose of zidovudine. The addition of recombinant EPO therapy three times weekly to patients did not result in further significant increases in BFU-E but did significantly increase hemoglobin. Our data suggest that recombinant G-CSF may be one of the hematopoietic factors that influences production of BFU-E and RBCs in humans.

Studies on Copper Metabolisn: II. Hematologic Manifestations of Copper Deficiency in Swine

1. A total of 70 swine were fed a diet consisting only of evaporated cow’s milk. Copper and iron were added to the diet of 10 of the pigs. Iron only was added to the diet of 46 of the pigs. Copper only was added to the diet of 10 of the pigs. Four pigs received neither iron or copper.2. The animals deficient in copper developed skeletal abnormalities, microcytic hypochromic anemia, leukopenia, neutropenia, normoblastic hyperplasia of the bone marrow, hypoferremia, an increase in the iron-binding capacity of the plasma, hypocupremia and reduced erythrocyte copper as well as tissue copper. No abnormality in porphyrin metabolism was observed and tissue as well as erythrocyte catalase activity was not significantly reduced. Following the administration of copper, the blood of the animals was rapidly and completely restored to normal.3. The animals deficient in iron developed a severe microcytic, hypochromic anemia, normoblastic hyperplasia of the bone marrow, hypoferremia and an increase in the total iron-binding capacity of the plasma. No abnormality in copper or porphyrin metabolism was observed in these animals except for a slight elevation in the plasma copper level and a marked increase in liver copper.4. The animals deficient in both copper and iron developed all of the manifestations noted in the copper-deficient pigs. These changes occurred more rapidly and to a greater degree than in the swine with a deficiency of either element alone.5. The morphologic and biochemical similarities between anemia due to copper deficiency and anemia due to iron deficiency suggest that in copper-deficient swine there is an abnormality in the metabolism of iron and that, furthermore, the anemia may be the consequence of this abnormality.